Mayne Pharma Group Limited
http://www.maynepharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mayne Pharma Group Limited
US And EU Approvals In First Half 2021 Underscore US-First Orientation Of Novel Drug Development
Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.
Keeping Track: US FDA Approval Binge Includes Brexafemme, Wegovy, Ryplazim, Truseltiq, Lybalvi, Tembexa
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Keeping Track: US FDA Clears Oncologics Tukysa And Jelmyto; Regeneron Anti-Ebola Cocktail Under Review
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Distributors
- Pharmaceuticals
- Services
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
-
Laboratory Testing Services
- Anatomical Pathology
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Halcygen Pharmaceuticals
- Mayne Pharma International
- Mayne Pharma Ventures Pty Ltd